Who Will Win the Hepatitis C Market?

A new hepatitis C drug has come onto the scene — Merck’s boceprevir — after a 10-year lull in HCV therapies entering the market.

ByEmerging Equities:Gilead Sciences (GILD) announced on May 21, 2013 that the European regulator EMA (European Medicines Agency) started the process of assessing the company's once daily oral treatment for hepatitis C virus (HCV) and will furnish an accelerated review

Zacks.com submits: Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Pharmasset, Inc. (VRUS), a clinical-stage pharmaceutical company, to develop a combination of two candidates, Bristol-Myers’ BMS-790052 and Pharmasset’s PSI-7977, for treating patients suff

Jason Chew submits: Pegylated interferon plus ribavirin is the current standard of care for HCV treatment. However, it is a 48-week treatment and is only effective in about 50% of patients.

By Ry Frank:I believe the best investments in the biotech market are in companies focused on the treatment of chronic diseases. There are many people suffering from diseases for which there are no cures, but medical science has developed ways to manage these illnesses and make it possible to live a full life, even when a person is sick. One of the diseases that fit into this category is hepatitis C. There are several companies focused on the treatment and management of hepatitis C and its side effects.

By Matt Schilling:There is no doubt Hepatitis C is one of the deadliest and most painful diseases any one can endure, and in an effort to fight back against its deadly wrath, Achillion Pharmaceuticals (ACHN) is making considerable strides in terms of four drugs currently in its pipeline.

By LifeSci Advisors: By Shilpa Siddhi, M.S., M.B.A.

Prohost Biotech submits:Better than expected results were announced from a phase 3 randomized, double-blind, placebo-controlled ADVANCE study with Vertex’ (VRTX) hepatitis C drug telaprevir.